000K  utf8
1100  $c2022
1500  eng
2050  urn:nbn:de:gbv:8:3-2022-00501-3
2051  10.3389/fimmu.2022.932155
3000  Chan, Chilam
3010  Baumann, Niklas
3010  Leusen, Jeanette H. W.
3010  Lustig, Marta
3010  Valerius, Thomas
3010  van Tetering, Geert
4000  Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy$dA Novel Anti-Cancer Strategy With IgA Antibodies?  [Chan, Chilam]
4209  Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells have a deleterious impact on clinical responses to therapeutic antibodies. Myeloid checkpoints, which negatively regulate macrophage and neutrophil anti-tumor responses, are a novel type of checkpoint molecule. Myeloid checkpoint inhibition is currently being studied in combination with IgG-based immunotherapy. In contrast, the combination with IgA-based treatment has received minimal attention. IgA antibodies have been demonstrated to more effectively attract and activate neutrophils than their IgG counterparts. Therefore, myeloid checkpoint inhibition could be an interesting addition to IgA treatment and has the potential to significantly enhance IgA therapy.
4950  https://doi.org/10.3389/fimmu.2022.932155$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2022-00501-3$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/macau_mods_00002913
5051  610
5550  Antibodies
5550  Antigens, Differentiation
5550  Cancer Immonotherapy
5550  CD47 Antigen
5550  Cd47-sirpalpha Axis
5550  Humans
5550  IGA
5550  Immune Checkpoint
5550  Immunoglobulin A
5550  Immunoglobulin G
5550  Macrophages
5550  Myeloid Checkpoints
5550  Neoplasms
5550  Neutrophils (Pmns)
5550  Phagocytosis
5550  Receptors, Immunologic